BDSI remains committed to the chronic pain community during the COVID-19 pandemic. For more
information on access to our products, please call our customer service line at 1-800-469-0261.
BDSI helps develop technologies designed to deliver increased bioavailability in the treatment of serious and debilitating chronic conditions.
BioErodible MucoAdhesive (BEMA®) technology uses a small polymer film applied to the inner lining of the cheek for rapid drug administration. Delivering medication across the mucous membranes, this bioerodible film helps optimize time-sensitive treatments. It is also beneficial for facilitating the administration of drugs where poor oral absorption is an issue.
RALEIGH, N.C. , May 29, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International , Inc. (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey Bailey , Interim Chief Executive
Read moreRALEIGH, N.C. , May 11, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences International, Inc (NASDAQ: BDSI), a rapidly growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, today announced that Jeffrey A.
Read moreFirst Quarter Total Company Net Sales Increased 94% versus Prior Year to $38.3 Million First Quarter BELBUCA® Net Sales Increased 79% versus Prior Year to $33.5 Million Conference Call and Webcast Scheduled for 4:30 PM EST Today RALEIGH, N.C. , May 07, 2020 (GLOBE NEWSWIRE) -- BioDelivery Sciences
Read moreStay up to date on the latest news
Get started now